Cite

HARVARD Citation

    Atkins, M. et al. (2021). Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. European journal of cancer. pp. 1-10. [Online]. 
  
Back to record